Today Top Buzzing Stocks Are Dominating the Gainers List

 Top.Gainers
 
  Top.Gainers
 
Follow  Message
 
 
 
Top.Gainers highlighting the top gainers of the day, providing timely updates and insights on the market's highest achievers.
 

•  02 Jun 2025
 

$LYRA was the undisputed rocket ship of the day, catapulting an astonishing 310.75% after delivering highly anticipated results from its ENLIGHTEN 2 Phase 3 trial. The trial of LYR-210 for chronic rhinosinusitis (CRS) not only met its primary endpoint but also hit key secondary endpoints across both patient subgroups. That’s a rare clinical double strike and it lit a fire under the stock with volume surging from a daily average of just 116K shares to a massive 26.5 million. When a micro-cap biotech lands a successful Phase 3, Wall Street listens and with results showing strong statistical significance, LYRA may have just earned a new valuation floor.

$APLD surged 48.46% as traders digested the magnitude of its $7 billion, 15-year lease deal with CoreWeave, an AI hyperscaler. The agreement will see Applied delivering 250 megawatts of IT capacity at its North Dakota data center, securing multi-billion-dollar visibility in one of the market’s hottest growth sectors. Layer on heavy options activity flagged by unusual call buying across a $7–$15 range and APLD suddenly looks like a breakout story that even institutional money can't ignore.

$KYMR popped 45.51% after announcing positive Phase 1 data for KT-621, its first-in-class oral STAT6 degrader. The healthy volunteer data not only met expectations it exceeded Kymera’s internal target product profile. For traders betting on novel mechanisms in immunology and inflammation, this is a fundamental de-risking event that sets up further upside into Phase 2 development.

$HYPR rallied 41.08% after securing FDA clearance for its next-gen portable MRI system. The announcement emphasized improved image quality and advanced AI software capabilities sending shares soaring on an unprecedented 102 million shares traded (vs. a typical 415K). When microcaps like HYPR get regulatory greenlights, especially in the medtech space, the follow-through can be swift and strong although volatility is part of the game.

$PSTV rose 28.16% despite underwhelming earnings, and $CLF jumped 23.16% on broader industrial momentum. But their gains felt more like sympathy plays rather than catalysts-driven surges, especially compared to the biotech and AI standouts above.